Yuji Miura1, Masahiko Ando2, Kentaro Yamazaki3, Shuichi Hironaka4, Narikazu Boku5, Kei Muro6, Ichinosuke Hyodo7. 1. Department of Medical Oncology, Toranomon Hospital, 2-2-2 Toranomon, Minato-ku, Tokyo, 105-8470, Japan. yujmiura@mac.com. 2. Department of Advanced Medicine, Nagoya University Hospital, Nagoya, Japan. 3. Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan. 4. Department of Medical Oncology and Hematology, Oita University Faculty of Medicine, Oita, Japan. 5. Division of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. 6. Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan. 7. Division of Gastroenterology, University of Tsukuba, Tsukuba, Japan.
Abstract
PURPOSE: Cumulative sensory neurotoxicity induced by oxaliplatin impairs patients' quality of life and treatment continuation. This study investigated the relationship between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy (OIPN) during treatment of metastatic colorectal cancer (mCRC) over time. METHODS: A post hoc analysis was conducted for 191 patients with mCRC who received mFOLFOX6 plus bevacizumab in the WJOG4407G trial. Physician-assessed OIPN was graded by CTCAE every 2 weeks. Patient-reported OIPN was assessed with the FACT/GOG-Ntx (11 items, best score 44) at baseline and at 3, 6, and 9 months. Physician underestimation was defined as when the highest scores of the NTX1-4 sensory subscale/CTCAE grade were 2/0, 3/0-1, or 4/0-1, and overestimation as 0/2-3, 1/2-3, or 2/3. RESULTS: The median total dose (range) of oxaliplatin was 762 (85-5950) mg/m2. Overall, the least squares mean of FACT/GOG-Ntx scores (standard error), estimated by a linear mixed model, were 36 (0.8), 34 (0.9), 29 (1.0), and 27 (1.1) for CTCAE grades 0, 1, 2, and 3, respectively. FACT/GOG-Ntx scores were weakly-to-moderately correlated with CTCAE grade (Spearman's r = - 0.24 [p = 0.0026], - 0.46 [p < 0.0001], and - 0.56 [p < 0.0001] at 3, 6, and 9 months, respectively). OIPN was underestimated in 85/159 (54%), 43/109 (39%), and 18/69 (26%) patients at 3, 6, and 9 months, respectively. In contrast, OIPN was overestimated in less than 5% of the patients at any time. CONCLUSION: During early treatment, physician underestimation of OIPN in patients with mCRC is likely.
PURPOSE: Cumulative sensory neurotoxicity induced by oxaliplatin impairs patients' quality of life and treatment continuation. This study investigated the relationship between physician-assessed and patient-reported oxaliplatin-induced peripheral neuropathy (OIPN) during treatment of metastatic colorectal cancer (mCRC) over time. METHODS: A post hoc analysis was conducted for 191 patients with mCRC who received mFOLFOX6 plus bevacizumab in the WJOG4407G trial. Physician-assessed OIPN was graded by CTCAE every 2 weeks. Patient-reported OIPN was assessed with the FACT/GOG-Ntx (11 items, best score 44) at baseline and at 3, 6, and 9 months. Physician underestimation was defined as when the highest scores of the NTX1-4 sensory subscale/CTCAE grade were 2/0, 3/0-1, or 4/0-1, and overestimation as 0/2-3, 1/2-3, or 2/3. RESULTS: The median total dose (range) of oxaliplatin was 762 (85-5950) mg/m2. Overall, the least squares mean of FACT/GOG-Ntx scores (standard error), estimated by a linear mixed model, were 36 (0.8), 34 (0.9), 29 (1.0), and 27 (1.1) for CTCAE grades 0, 1, 2, and 3, respectively. FACT/GOG-Ntx scores were weakly-to-moderately correlated with CTCAE grade (Spearman's r = - 0.24 [p = 0.0026], - 0.46 [p < 0.0001], and - 0.56 [p < 0.0001] at 3, 6, and 9 months, respectively). OIPN was underestimated in 85/159 (54%), 43/109 (39%), and 18/69 (26%) patients at 3, 6, and 9 months, respectively. In contrast, OIPN was overestimated in less than 5% of the patients at any time. CONCLUSION: During early treatment, physician underestimation of OIPN in patients with mCRC is likely.
Authors: Sebastian W Nielsen; Simone Dyring Hasselsteen; Helena Sylow Heilmann Dominiak; Dejan Labudovic; Lars Reiter; Susanne Oksbjerg Dalton; Jørn Herrstedt Journal: Support Care Cancer Date: 2022-08-06 Impact factor: 3.359
Authors: Sebastian W Nielsen; Sanne Lindberg; Christina Halgaard Bruvik Ruhlmann; Lise Eckhoff; Jørn Herrstedt Journal: J Clin Med Date: 2022-03-27 Impact factor: 4.241